A phase 1b/2 multiple-dose safety study and pharmacokinetic/pharmacodynamic study of LY2189102 in patients with rheumatoid arthritis
Phase of Trial: Phase I/II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs LY 2189102 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 09 Oct 2008 Checked against the ClinicalTrials.gov record.
- 30 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.